Epic Sciences

10.03.2018 / New York / San Diego Back to News Listings

Epic Sciences Continues Research on Multiple Fronts; Remains Quiet on Dx Development Pipeline

With its first commercial diagnostic now fully launched and awaiting a final coverage decision by Medicare, Epic Sciences is keeping quiet about concrete plans for a pipeline of additional clinical assays, though it continues to collect data from research studies which may provide possibilities for future translation.

One interesting new application was hinted at in a pharmaceutical study published in JAMA Oncology earlier this summer. Investigators applied Epic's cell-analysis technology to blood samples from metastatic prostate cancer patients treated with Bind Therapeutics' investigational BIND-014, an anti-PSMA antibody-drug conjugate (ADC).

Read the full story on GenomeWeb.